Átmenettan és közgazdaságtan. Módszertani tanulságok egy részterület műveléséből (Transitology and economics. Methodological lessons to be drawn from work in a partial territory)

Az akadémiai székfoglaló előadás a teljesség igénye nélkül arra a kérdésre keresi a választ, hogy a posztkommunista átalakulás tanulmányozása milyen hasznosítható tanulságokkal szolgált a közgazdasági elmélet művelőinek szélesebb köre számára. Megállapítja, hogy - a világ közgazdaságtanában folyó megújulással párhuzamosan - a módszertani pluralizmus, ezen belül a történeti, az intézményi és az összehasonlító gazdaságtani közelítés visszahelyezése jogaiba, valamint az egyoldalúan csak a matematikai formalizálást előtérbe állító megoldások visszaszorulása figyelhető meg. _____ This inaugural lecture delivered on receiving membership of the Hungarian Academy of Sciences seeks, without attempting completeness, to examine what useful lessons could be drawn from study of the post-communist transformation for practitioners in wider fields of economics. It establishes that methodological pluralism, including the rights of historical, institutional and comparative economic approaches, is being relegated by the renewal taking place in world economics. This can be seen to be constricting the approaches that place mathematical formalism to the fore.

Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis.

OBJECTIVES: To compare the efficacy and safety of infliximab-biosimilar with other biological drugs for the treatment of active ankylosing spondylitis (AS). METHODS: Systematic literature review for randomized controlled trials (RCTs) with adalimumab, etanercept, golimumab, infliximab and infliximab-biosimilar in AS was performed and indirect meta-analysis (Bayesian mixed treatment comparison) was carried out. The proportion of patients reaching 20 % improvement by the assessment of Spondyloarthritis International Society response criteria (ASAS20) at weeks 12 and 24 was used as efficacy endpoints, and the occurrence of serious adverse events at week 24 was applied to compare the safety of the biologicals. RESULTS: Altogether, 13 RCTs, identified by the systematic literature search, were included in the analysis. Results on the ASAS20 efficacy endpoint were reported for week 12 in 12 RCTs involving 2,395 patients, and for week 24 in 5 RCTs comprising 1,337 patients. All the five biological agents proved to be significantly superior to placebo. Infliximab showed the highest odds ratio (OR) of 7.2 (95 % CI 3.68-13.19) compared to placebo, followed by infliximab-biosimilar with OR 6.25 (95 % CI 2.55-13.14), both assessed at week 24. No significant difference was found between infliximab-biosimilar and other biological treatments regarding their efficacy and safety. CONCLUSIONS: This is the first study which includes a biosimilar drug in the meta-analysis of biological treatments in AS. The results have proven the similar efficacy and safety profile of infliximab-biosimilar treatment compared to other biologicals.